Department of Pharmacology, and Cleveland Center for Membrane and Structural Biology, School of Medicine, 2546Case Western Reserve University, Cleveland, OH 44106, USA.
Exp Biol Med (Maywood). 2020 Nov;245(17):1615-1625. doi: 10.1177/1535370220926938. Epub 2020 May 21.
Age-related macular degeneration (AMD) is a devastating retinal degenerative disease. Epidemiological reports showed an expected increasing prevalence of AMD in the near future. The only one existing FDA-approved pharmacological treatment involves an anti-vascular endothelial growth factor (VEGF) therapy with serious disadvantages. This limitation emphasizes an alarming need to develop new therapeutic approaches to prevent and treat AMD. In this review, we summarize scientific data unraveling the therapeutic potential of the specific retinoid and natural compounds. The experimental results reported by us and other research groups demonstrated that retinoid analogs and compounds with natural product scaffolds could serve as lead compounds for the development of new therapeutic agents with potential to prevent or slow down the pathogenesis of AMD.
年龄相关性黄斑变性(AMD)是一种破坏性的视网膜退行性疾病。流行病学报告显示,AMD 在不久的将来的患病率预计会增加。唯一一种获得 FDA 批准的药物治疗方法涉及抗血管内皮生长因子(VEGF)治疗,但存在严重的缺陷。这种局限性强调了开发新的治疗方法来预防和治疗 AMD 的迫切需要。在这篇综述中,我们总结了揭示特定类视黄醇和天然化合物治疗潜力的科学数据。我们和其他研究小组报告的实验结果表明,类视黄醇类似物和具有天然产物骨架的化合物可以作为开发新的治疗药物的先导化合物,这些药物具有预防或减缓 AMD 发病机制的潜力。